ABSTRACT BOOK ABSTRACTS



A new ERA for global Dermatology 10 - 15 JUNE 2019 MILAN, ITALY

MELANOMA AND MELANOCYTIC NAEVI

LIPID MEDIATOR LIPOXIN A4 EXERTS ANTI-TUMOR EFFECTS IN MELANOMA

Ling Li⁽¹⁾

School Of Medicine Of University Of Electronic Science And Technology, Department Of Dermatology, institute Of Dermatology And Venereology, Sichuan Academy Of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China⁽¹⁾

Introduction:Lipoxin A4 (LXA4) was previously considered an anti-inflammatory lipid mediator, and its anti-tumor potential was proposed recently. However, the underlying molecular and cellular basis of the therapeutic effect of LXA4 in melanoma remains unclear.

Objectives: This study investigates the regulatory role of LXA4 and its analog on melanoma invasion in vitro and vivo.

Methods:The LXA4 receptor (ALXR) was expressed in both melanoma tissues and A375 cells. The invasion and apoptosis abilities of A375 cells, and the anti-tumor effects of LXA4 in vivo with a mouse model were examined.

Results:ALXR was abundantly expressed in A375 cell lines and melanoma tissues. LXA4 could attenuate A375 cell invasion significantly. BML-111, an agonist of LXA4 receptor, tended to control the tumor development in a A375 melanoma model.

Conclusions:LXA4 and its analog may be potential therapeutic option for melanoma invasion.



24TH WORLD CONGRESS OF DERMATOLOGY MILAN 2019



International League of Dermatological Societies Skin Health for the World

